Addex Therapeutics Ltd
ADXN
$9.00
$0.19172.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -97.27% | |||
| Total Other Revenue | -- | -100.00% | |||
| Total Revenue | 4,547.06% | -97.48% | |||
| Cost of Revenue | 133.33% | -68.53% | |||
| Gross Profit | -30.12% | 56.98% | |||
| SG&A Expenses | 33.38% | -21.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.96% | -35.28% | |||
| Operating Income | -32.91% | 29.47% | |||
| Income Before Tax | -20.92% | 23.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.92% | 23.28% | |||
| Earnings from Discontinued Operations | -- | -546.43% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.33% | 22.38% | |||
| EBIT | -32.91% | 29.47% | |||
| EBITDA | -39.91% | 26.94% | |||
| EPS Basic | -19.29% | 22.22% | |||
| Normalized Basic EPS | -20.93% | 23.21% | |||
| EPS Diluted | -19.29% | 39.66% | |||
| Normalized Diluted EPS | -20.93% | 23.21% | |||
| Average Basic Shares Outstanding | 0.01% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||